Art. -Nr.: HY-101903

BMS-309403

29 Cited Publications

Kundenbewertung

Based on 29 publication(s) in Google Scholar

BMS-309403 is a potent, orally active and selective adipocyte fatty acid binding protein (also known as FABP4, aP2) inhibitor with K_is of <2, 250, and 350 nM for FABP4, FABP3, and FABP5, respectively. BMS-309403 interacts with the fatty-acid-binding pocket within the interior of the protein and competitively inhibits the binding of endogenous fatty acids. BMS-309403 improves endothelial function in apolipoprotein E-deficient mice and in cultured human endothelial cells.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.91%
CAS. Nr.: 300657-03-8
Formel: C₃₁H₂₆N₂O₃
Molecular Weight:474.55

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

BMS-309403 Chemical Structure

CAS. Nr.: 300657-03-8

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Publications (29)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

Ki: less than 2 nM (FABP4), 250 nM (FABP3), 350 nM (FABP5)^[1]

In Vitro

Treatment with BMS-309403 significantly decreased MCP-1 production from THP-1 macrophages in a dose- and time-dependent manner^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

BMS-309403 sodium (15 mg/kg; chronic treatment; daily for 6 weeks) improves endothelial function, phosphorylated and total eNOS and reduced plasma triglyceride levels but did not affect endothelium-independent relaxations^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

C57BL/6J mice (ApoE^−/− mice)^[3]
Dosage:

15 mg/kg
Administration:

Chronic treatment ; daily for 6 weeks
Result:

Significantly increased the phosphorylated eNOS (Ser1177) and total eNOS but not the phosphorylated to total eNOS ratio in aortae of 18 weeks old ApoE^−/− mice.

Chemical Information

CAS. Nr. 300657-03-8
Appearance Solid
Molecular Weight 474.55
Formel C₃₁H₂₆N₂O₃
Color White to off-white
SMILES

O=C(O)COC1=CC(C2=CC=CC=C2N3N=C(C4=CC=CC=C4)C(C5=CC=CC=C5)=C3CC)=CC=C1
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (29)

All Cell Imaging/StainingIn Vivo Efficacy StudyHistological Imaging/StainingWB

Sort by:

Journal Impact Factor

Bone Res

FABP4 secreted by M1-polarized macrophages promotes synovitis and angiogenesis to exacerbate rheumatoid arthritis. [Abstract]

2022 Jun 22;10(1):45. PMID: 35729106

BMS-309403 purchased from MedChemExpress. Usage Cited in: Bone Res. 2022 Jun 22;10(1):45. [Abstract]

The effect of FABP4 and M1-polarized macrophage supernatant on HUVECs, FLSs, and chondrocytes in vitro. Tube formation assay and quantification of HUVECs cultured with vehicle (C), rhFABP4 (P), rhFABP4 + BMS309403 (20 μmol/L, 1h) (PB). Scale bar: 100 µm.

BMS-309403 purchased from MedChemExpress. Usage Cited in: Bone Res. 2022 Jun 22;10(1):45. [Abstract]

The effect of FABP4 and M1-polarized macrophage supernatant on HUVECs, FLSs, and chondrocytes in vitro. Tube formation assay and quantification of HUVECs cultured with vehicle (C), M1-polarized macrophage supernatant (S), or M1-polarized macrophage supernatant+BMS309403 (20 μmol/L, 1h) (SB) (n = 3 per group). Scale bar: 100 µm.

BMS-309403 purchased from MedChemExpress. Usage Cited in: Bone Res. 2022 Jun 22;10(1):45. [Abstract]

Representative images and quantification of FABP4 immunohistochemical staining and coimmunostaining of FABP4 with F4/80 or NOS2 in the synovium of TSC1KO mice treated with vehicle, BMS309403 (5 mg/kg, ip, twice a week) or anagliptin for 4 weeks after AIA modeling (n = 10 per group). Scale bar: 12.5 µm and 100 µm.

BMS-309403 purchased from MedChemExpress. Usage Cited in: Bone Res. 2022 Jun 22;10(1):45. [Abstract]

Representative images and quantification of FABP4 immunohistochemical staining and coimmunostaining of FABP4 with F4/80 or NOS2 in the synovium of TSC1KO mice treated with vehicle, BMS309403 (5 mg/kg, ip, twice a week) or anagliptin for 8 weeks after AIA modeling (n = 10 per group). Scale bar: 12.5 µm and 100 µm.
Nat Commun

Ascites protects against ferroptosis and enables the peritoneal growth of ovarian cancer. [Abstract]

2026 May 11;17(1):4190. PMID: 42115216
Cell Death Dis

FABP4 contributes to renal interstitial fibrosis via mediating inflammation and lipid metabolism. [Abstract]

2019 May 16;10(6):382. PMID: 31097687
Cancer Lett

FABP4 in macrophages facilitates obesity-associated pancreatic cancer progression via the NLRP3/IL-1β axis. [Abstract]

2023 Oct 28:575:216403. PMID: 37741433

BMS-309403 purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2023 Oct 28:575:216403. [Abstract]

STAM mice were treated with small-molecule inhibitors targeting LPL (Orlistat, S+O), FABP4 (BMS309403 (15 mg/kg, ip, twice a week), S+B), or CPT1 (Etomoxir, S+E). Tumor burden was reduced in all inhibitor-treated groups compared to the STAM control group.
Int J Biol Sci

Targeted Inhibition of LPL/FABP4/CPT1 fatty acid metabolic axis can effectively prevent the progression of nonalcoholic steatohepatitis to liver cancer. [Abstract]

2021 Oct 11;17(15):4207-4222. PMID: 34803493
Antioxidants (Basel)

Genipin Attenuates Diabetic Cognitive Impairment by Reducing Lipid Accumulation and Promoting Mitochondrial Fusion via FABP4/Mfn1 Signaling in Microglia. [Abstract]

2022 Dec 29;12(1):74. PMID: 36670935
Free Radic Biol Med

Loss of EMP1 promotes the metastasis of human bladder cancer cells by promoting migration and conferring resistance to ferroptosis through activation of PPAR gamma signaling. [Abstract]

2022 Aug 20:189:42-57. PMID: 35850179
Clin Transl Med

Adipocyte fatty acid-binding protein as a cerebrospinal fluid-accessible biomarker and druggable target in subarachnoid haemorrhage: Linking fatty acid dysregulation to microglial neuroinflammation. [Abstract]

2026 Feb;16(2):e70607. PMID: 41612866
Clin Transl Med

FABP4-mediated lipid droplet accumulation drives epithelial-mesenchymal transition and aggravates alveolar epithelial barrier disruption. [Abstract]

2026 Jan;16(1):e70563. PMID: 41454478
EMBO Mol Med

Saturated fatty acids induce lipotoxicity in lymphatic endothelial cells contributing to secondary lymphedema development. [Abstract]

2025 Aug 4. PMID: 40759794
J Med Chem

Discovery of Highly Potent, Selective, and Liver-Targeting HSD17B13 Inhibitor with Robust In Vivo Anti-MASH Activity. [Abstract]

2025 Jun 12;68(11):11127-11148. PMID: 40387207
Biochem Pharmacol

Rhein suppresses osteosarcoma progression via modulating the miR-328-3p/TCF7L2/FABP4 axis. [Abstract]

2025 Jul 11:241:117152. PMID: 40653025
Cell Mol Life Sci

Integrated multi-omic analysis identifies fatty acid binding protein 4 as a biomarker and therapeutic target of ischemia-reperfusion injury in steatotic liver transplantation. [Abstract]

2024 Feb 10;81(1):83. PMID: 38341383
Oncogenesis

Fatty acid uptake mediated by FABP4 promotes the formation of CD8+T cell senescence through lipid peroxidation in the adipocyte-rich microenvironment of Ovarian Cancer. [Abstract]

2026 Feb 6;15(1):9. PMID: 41651808
Cancer Immunol Immunother

Promoting APC function of B cells via reprogramming the fatty acid metabolism enhances anticancer immunity in metastatic ovarian cancer. [Abstract]

2026 Apr 15;75(5):145. PMID: 41984099
Eur J Pharmacol

Pharmacological inhibition of fatty acid-binding protein 4 alleviates sepsis-associated acute kidney injury in mice via suppressing ferroptosis. [Abstract]

2026 May 30:1030:179061. PMID: 42219054
Int Immunopharmacol

Interleukin-10 increases macrophage-mediated chemotherapy resistance via FABP5 signaling in multiple myeloma. [Abstract]

2023 Sep 2;124(Pt A):110859. PMID: 37666065
Mol Neurobiol

Fatty Acid-binding Protein 4 Exacerbates Blood-brain Barrier Disruption Through the JNK/c-Jun/MMP12 Pathway After Traumatic Brain Injury. [Abstract]

2025 Nov 21;63(1):130. PMID: 41269411
BMC Chem

Discovery of novel FABP1 inhibitors for the treatment of metabolic dysfunction-associated steatohepatitis and hepatic fibrosis. [Abstract]

2025 Sep 30;19(1):270. PMID: 41029781
Indian J Dermatol Venereol Leprol

FABP5 reprograms lipid metabolism and promotes cutaneous T-cell lymphoma progression via activation of PPARγ signalling. [Abstract]

2025 Jul 4:1-13. PMID: 40826877
Food Chem Toxicol

Inhibiting fatty acid-binding protein 4 reverses inflammation and apoptosis in wasp sting-induced acute kidney injury. [Abstract]

2025 Apr 2:115428. PMID: 40185302
Iran J Basic Med Sci

Inhibition of FABP4 attenuates cardiac fibrosis through inhibition of NLRP3 inflammasome activation. [Abstract]

2022 Oct;25(10):1260-1266. PMID: 36311201
Br J Nutr

PPARγ regulates fabp4 expression to increase DHA content in golden pompano ( Trachinotus ovatus) hepatocytes. [Abstract]

2022 Jan 14;127(1):3-11. PMID: 33663633
J Proteomics

Identification and characterization of proteins that are differentially expressed in adipose tissue of olanzapine-induced insulin resistance rat by iTRAQ quantitative proteomics. [Abstract]

2020 Feb 10;212:103570. PMID: 31706944
Am J Cancer Res

25-HC promotes hepatocellular carcinoma metastasis through up-regulation of TLR4 dependent FABP4. [Abstract]

2019 Oct 1;9(10):2140-2155. PMID: 31720079

BMS-309403 purchased from MedChemExpress. Usage Cited in: Am J Cancer Res. 2019 Oct 1;9(10):2140-2155. [Abstract]

FABP4 expression is up-regulated in the metastatic tumor sites. BALB/C nude mice are intrahepatic inoculation of 5 × 10⁶ HepG2 cells followed by intraperitoneally injection with PBS or 25-HC (10 mg/kg) or 25-HC with BMS-309403 (45 mg/kg). At the end of the experiment, mice are sacrificed, the tumor tissues in the livers of the mice without metastasis, with abdominal metastasis and the metastatic tumor sites are extracted. The mRNA and protein expression of FABP4 is assessed by RT-qPCR
Comp Biochem Physiol B Biochem Mol Biol

Fabp4 contributes toward regulating inflammatory gene expression and oxidative stress in Ctenopharyngodon idella. [Abstract]

2022 Apr-May:259:110715. PMID: 34999220
Neurosci Lett

Effects of pharmacological inhibition of FABP4 during gestation and lactation on offspring neurodevelopment and behavior. [Abstract]

2025 Mar 28:853:138199. PMID: 40090510
Parasitol Res

Effects of host fatty acid-binding protein 4 on Eimeria tenella sporozoites invasion of cells. [Abstract]

2019 Jun;118(6):1919-1926. PMID: 31069534
Res Sq

2026 Jun 15.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 175 mg/mL (368.77 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.1073 mL

10.5363 mL

21.0726 mL

5 mM

0.4215 mL

2.1073 mL

4.2145 mL

10 mM

0.2107 mL

1.0536 mL

2.1073 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (4.38 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (4.38 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (280 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Sulsky R, et al. Potent and selective biphenyl azole inhibitors of adipocyte fatty acid binding protein (aFABP). Bioorg Med Chem Lett. 2007 Jun 15;17(12):3511-5. [Content Brief]

[2]. Lin W, et al. BMS309403 stimulates glucose uptake in myotubes through activation of AMP-activated protein kinase. PLoS One. 2012;7(8):e44570. [Content Brief]

[3]. Lee MY, et al. Chronic administration of BMS309403 improves endothelial function in apolipoprotein E-deficient mice and in cultured human endothelial cells. Br J Pharmacol. 2011 Apr;162(7):1564-76. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.1073 mL	10.5363 mL	21.0726 mL	52.6815 mL
	5 mM	0.4215 mL	2.1073 mL	4.2145 mL	10.5363 mL
	10 mM	0.2107 mL	1.0536 mL	2.1073 mL	5.2681 mL
	15 mM	0.1405 mL	0.7024 mL	1.4048 mL	3.5121 mL
	20 mM	0.1054 mL	0.5268 mL	1.0536 mL	2.6341 mL
	25 mM	0.0843 mL	0.4215 mL	0.8429 mL	2.1073 mL
	30 mM	0.0702 mL	0.3512 mL	0.7024 mL	1.7560 mL
	40 mM	0.0527 mL	0.2634 mL	0.5268 mL	1.3170 mL
	50 mM	0.0421 mL	0.2107 mL	0.4215 mL	1.0536 mL
	60 mM	0.0351 mL	0.1756 mL	0.3512 mL	0.8780 mL
	80 mM	0.0263 mL	0.1317 mL	0.2634 mL	0.6585 mL
	100 mM	0.0211 mL	0.1054 mL	0.2107 mL	0.5268 mL

Keywords

BMS-309403

29 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

BMS-309403

Metabolism/Protease Compound Library

Anti-Cardiovascular Disease Compound Library

Orally Active Compound Library

Lipid Metabolism Compound Library

Targeted Diversity Library

Human Metabolite Library

Heterocyclic Compound Library

Metabolic Enzyme Compound Library

Highly Selective Inhibitors Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Publications Citing Use of MedChemExpress (MCE) BMS-309403

Biologische Aktivität

Chemical Information

Publications (29)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

BMS-309403

Metabolism/Protease Compound Library

Anti-Cardiovascular Disease Compound Library

Orally Active Compound Library

Lipid Metabolism Compound Library

Targeted Diversity Library

Human Metabolite Library

Heterocyclic Compound Library

Metabolic Enzyme Compound Library

Highly Selective Inhibitors Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Publications Citing Use of MedChemExpress (MCE) BMS-309403

Biologische Aktivität

Chemical Information

Publications (29)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

BMS-309403 Related Classifications

HY-101903 Related Classifications